Batey Robert G, Salmond Ses J, Bensoussan Alan
Faculty of Health, University of Newcastle, Australia, PO Box 119, Wallsend NSW 2287, Australia.
Curr Gastroenterol Rep. 2005 Feb;7(1):63-70. doi: 10.1007/s11894-005-0068-z.
Interest in and use of complementary and alternative medicines (CAM) in the treatment of chronic liver diseases has increased in the past decade. However, this has not been supported by a significant increase in sound clinical research evidence for their efficacy. The research literature is growing, providing improved knowledge on population use of CAM, possible mechanisms of action of a large range of complementary and alternative medications, and possible specific indications for these agents in patients with liver disease. Although curative potential for CAM has not been documented consistently in any liver disorder, it is possible to identify anti-inflammatory activity and cytoprotective capacity for a number of agents from different branches of the world of CAM. Evidence grows for potential harm from an increasing number of compounds. Concurrently, clarity is increasing in relation to which specific constituents cause the harm and the mechanisms by which damage is produced.
在过去十年中,补充和替代医学(CAM)在慢性肝病治疗中的应用和关注度有所增加。然而,其疗效方面可靠的临床研究证据并未显著增加,无法为此提供支持。相关研究文献不断增多,使人们对CAM在人群中的使用情况、多种补充和替代药物可能的作用机制以及这些药物在肝病患者中的可能特定适应症有了更多了解。尽管在任何肝脏疾病中,CAM的治愈潜力都未得到一致证实,但从CAM领域的不同分支中,有多种药物已被证实具有抗炎活性和细胞保护能力。越来越多的化合物显示出潜在危害,相关证据不断增加。与此同时,对于哪些特定成分会造成危害以及产生损害的机制也越来越清晰。